EYEN Eyenovia, Inc. Stock Quote

EYEN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	15.90%	Shs Outstand	30.01M	Perf Week	0.59%
Market Cap	55.69M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	7.40%	Shs Float	24.87M	Perf Month	-1.72%
Income	-14.80M	PEG	-	EPS next Q	-0.19	Inst Own	14.80%	Short Float	0.48%	Perf Quarter	-10.94%
Sales	12.00M	P/S	4.64	EPS this Y	48.30%	Inst Trans	-0.17%	Short Ratio	0.83	Perf Half Y	-48.18%
Book/sh	0.99	P/B	1.73	EPS next Y	30.60%	ROA	-40.10%	Target Price	13.33	Perf Year	-59.76%
Cash/sh	0.82	P/C	2.09	EPS next 5Y	-	ROE	-80.50%	52W Range	1.59 - 6.63	Perf YTD	-57.25%
Dividend	-	P/FCF	-	EPS past 5Y	-6.40%	ROI	-44.90%	52W High	-74.81%	Beta	1.88
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	-	Gross Margin	93.30%	52W Low	5.03%	ATR	0.11
Employees	43	Current Ratio	2.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.14	Volatility	7.11% 6.27%
Optionable	Yes	Debt/Eq	0.26	EPS Q/Q	-15.80%	Profit Margin	-	Rel Volume	3.64	Prev Close	1.71
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 AMC	Payout	-	Avg Volume	143.27K	Price	1.67
Recom	1.70	SMA20	-2.79%	SMA50	-8.27%	SMA200	-40.54%	Volume	150,727	Change	-2.34%

Mar-01-21

Initiated

Northland Capital

Outperform

$10

Feb-03-20

Downgrade

Oppenheimer

Outperform → Perform

Aug-10-22 04:05PM	Eyenovia Reports Second Quarter 2022 Financial Results GlobeNewswire +5.42%
Aug-04-22 08:00AM	Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10 GlobeNewswire
Jul-27-22 08:00AM	Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member GlobeNewswire
Jul-18-22 08:00AM	Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations GlobeNewswire
Jul-07-22 08:00AM	Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors GlobeNewswire
Jul-06-22 08:00AM	Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China GlobeNewswire
Jun-29-22 08:53AM	Eyenovia (NASDAQ:EYEN) shareholders have endured a 65% loss from investing in the stock a year ago Simply Wall St.
Jun-09-22 10:09AM	UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders GlobeNewswire -5.19%
08:00AM	Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders GlobeNewswire
Jun-07-22 08:00AM	Eyenovia Announces Planned Chief Executive Officer Transition GlobeNewswire
May-15-22 08:06AM	Is Eyenovia (NASDAQ:EYEN) A Risky Investment? Simply Wall St.
May-12-22 04:05PM	Eyenovia Reports First Quarter 2022 Financial Results GlobeNewswire
May-05-22 08:00AM	Eyenovia to Report First Quarter 2022 Results on Thursday, May 12 GlobeNewswire
Apr-20-22 08:00AM	Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 GlobeNewswire
Apr-19-22 08:00AM	Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting GlobeNewswire
Apr-03-22 01:46PM	News Flash: One Analyst Just Made A Stunning Upgrade To Their Eyenovia, Inc. (NASDAQ:EYEN) Forecasts Simply Wall St.
Mar-31-22 01:17PM	Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
Mar-28-22 04:05PM	Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Mar-21-22 08:00AM	Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 GlobeNewswire
Mar-15-22 08:00AM	Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions GlobeNewswire
Mar-04-22 09:07AM	Eyenovia Raises 15M Via Equity To Advance MydCombi Program Benzinga
07:00AM	Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd. GlobeNewswire
Feb-13-22 06:29AM	Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN) Simply Wall St.
Feb-08-22 08:00AM	Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmission GlobeNewswire
Feb-07-22 08:30AM	Eyenovia Announces Changes to Board of Directors GlobeNewswire
Dec-10-21 05:46AM	Eyenovia (NASDAQ:EYEN) investors are sitting on a loss of 12% if they invested a year ago Simply Wall St.
Nov-17-21 12:00PM	Notable Eyenovia Insider Makes $360K Buy Benzinga
Nov-10-21 06:45PM	Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Eyenovia Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-08-21 08:00AM	Eyenovia to Participate in Myopia Panel Discussion at the [email protected] 2021 Meeting GlobeNewswire
Nov-05-21 03:25PM	CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10 GlobeNewswire
Nov-04-21 04:05PM	Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11 GlobeNewswire
08:00AM	Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia GlobeNewswire
07:34AM	4 Penny Stocks Insiders Are Buying Benzinga
03:14AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN PR Newswire
Nov-01-21 03:23PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN GlobeNewswire
Oct-29-21 05:28PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN Newsfile
Oct-28-21 07:40AM	3 Penny Stocks Insiders Are Buying Benzinga
Oct-26-21 11:00AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Eyenovia, Inc. (EYEN) Investigation ACCESSWIRE
Oct-25-21 02:31PM	Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; Bakkt Holdings Shares Spike Higher Benzinga -38.91%
12:11PM	Mid-Day Market Update: Crude Oil Rises Over 1%; ERYTECH Pharma Shares Plummet Benzinga
10:17AM	Mid-Morning Market Update: Markets Edge Higher; Kimberly Clark Cuts FY21 Forecast Benzinga
08:00AM	Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA GlobeNewswire
Oct-05-21 08:21AM	Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load? Simply Wall St. +9.07%
Oct-03-21 09:00AM	2 Healthcare Stocks With Big Catalysts in October TipRanks
Sep-30-21 06:38AM	Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-21-21 08:24AM	Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN) Simply Wall St.
Aug-19-21 07:28AM	Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-14-21 05:59AM	What Kind Of Investors Own Most Of Eyenovia, Inc. (NASDAQ:EYEN)? Simply Wall St.
Aug-11-21 04:05PM	Eyenovia Reports Second Quarter 2021 Financial Results GlobeNewswire
Jul-19-21 07:00AM	Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021 Business Wire
Jul-07-21 04:01PM	Eyenovia to Participate in Two Upcoming Investor Conferences GlobeNewswire
Jun-29-21 08:53AM	Where Do Hedge Funds Stand On Eyenovia, Inc. (EYEN)? Insider Monkey
Jun-15-21 08:00AM	Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue GlobeNewswire
May-26-21 09:13AM	Biotech Stock Roundup: MRNA's Vaccine Update & Pipeline Updates From REGN, BMY Zacks -5.03%
May-25-21 11:18AM	Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study Benzinga
09:03AM	Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia GlobeNewswire
May-12-21 04:05PM	Eyenovia Reports First Quarter 2021 Financial Results GlobeNewswire
02:30PM	Eyenovia, Inc. to Host Earnings Call ACCESSWIRE
May-10-21 08:30AM	Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank GlobeNewswire
May-05-21 08:00AM	Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12 GlobeNewswire
Apr-21-21 01:57AM	Insider Buying: Stuart Grant Just Spent US$294k On Eyenovia, Inc. (NASDAQ:EYEN) Shares Simply Wall St. +13.95%
Apr-01-21 07:30AM	Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors Business Wire
Mar-25-21 04:05PM	Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
02:30PM	Eyenovia, Inc. to Host Earnings Call ACCESSWIRE
Mar-23-21 07:30AM	Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi for Mydriasis Business Wire
Mar-18-21 08:00AM	Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25 GlobeNewswire
Mar-17-21 08:00AM	Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis Business Wire
Mar-10-21 08:00AM	Eyenovia to Participate in the 33rd Annual Roth Conference GlobeNewswire
Mar-08-21 12:24AM	Have Insiders Been Buying Eyenovia, Inc. (NASDAQ:EYEN) Shares This Year? Simply Wall St.
Mar-02-21 07:30AM	Eyenovia Announces FDA Acceptance of the MydCombi NDA Business Wire
Feb-16-21 08:00AM	Eyenovia to Host Key Opinion Leader Webinar on Presbyopia GlobeNewswire +6.16%
Jan-26-21 07:30AM	Eyenovia to Present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase Business Wire
Jan-06-21 08:00AM	Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event GlobeNewswire
Dec-29-20 07:00AM	Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually Business Wire
Dec-16-20 07:00AM	Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Business Wire
Dec-08-20 01:23AM	What Type Of Shareholders Own The Most Number of Eyenovia, Inc. (NASDAQ:EYEN) Shares? Simply Wall St.
Dec-03-20 07:00AM	Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End Business Wire
Dec-02-20 07:07PM	Is Eyenovia (EYEN) A Good Stock To Buy Now? Insider Monkey
Nov-10-20 04:06PM	Eyenovia Reports Third Quarter 2020 Financial Results GlobeNewswire
02:45PM	Eyenovia, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-20 03:30PM	These 3 Penny Stocks Could Rally Over 100%, Says Roth Capital TipRanks
Nov-05-20 08:00AM	Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10 GlobeNewswire
Oct-13-20 03:40PM	Bausch Acquires License for Myopia Solution from Eyenovia Zacks
07:00AM	Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million GlobeNewswire
Oct-12-20 07:00AM	Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12 PR Newswire +5.60%
Oct-05-20 07:00AM	Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting Business Wire
Sep-09-20 08:30AM	Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-26-20 07:31AM	Stuart Grant Just Bought 9.0% More Shares In Eyenovia, Inc. (NASDAQ:EYEN) Simply Wall St.
Aug-24-20 08:30AM	Eyenovia, Inc. Announces Underwriters Full Exercise of Over-Allotment Option in Public Offering GlobeNewswire
Aug-21-20 04:05PM	Eyenovia, Inc. Announces Closing of Offering of Common Stock GlobeNewswire
Aug-19-20 09:10AM	Eyenovia, Inc. Prices Public Offering of Common Stock GlobeNewswire -16.70%
Aug-18-20 04:03PM	Eyenovia, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-12-20 04:05PM	Eyenovia Reports Second Quarter 2020 Financial Results GlobeNewswire
07:29AM	The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private Benzinga
Aug-11-20 08:00AM	Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea GlobeNewswire +38.19%
Jul-29-20 08:30AM	Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results GlobeNewswire
Jul-20-20 03:30PM	3 Strong Buy Healthcare Stocks Under $5 That Could Double (Or More) TipRanks +8.89%
Jun-30-20 04:05PM	Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia GlobeNewswire
Jun-11-20 04:10PM	Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format GlobeNewswire

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grant Stuart M.	10% Owner	Jun 21	Buy	1.65	100,000	165,000	5,084,998	Jun 23 11:10 AM
LEE KENNETH B JR	Director	May 19	Buy	2.20	10,000	22,000	42,322	May 23 08:49 AM
MATHER CHARLES E IV	Director	May 18	Buy	2.03	7,000	14,232	48,322	May 19 08:27 AM
Grant Stuart M.	10% Owner	May 11	Buy	1.95	25,000	48,750	4,984,998	May 12 09:22 AM
Grant Stuart M.	10% Owner	May 10	Buy	1.98	50,000	99,000	4,959,998	May 12 09:22 AM
Grant Stuart M.	10% Owner	May 05	Buy	2.26	25,926	58,593	4,935,924	May 05 05:05 PM
Grant Stuart M.	10% Owner	May 04	Buy	2.26	24,074	54,407	4,909,998	May 05 05:05 PM
Grant Stuart M.	10% Owner	Apr 22	Buy	2.55	20,000	51,000	4,885,924	Apr 25 06:10 AM
Grant Stuart M.	10% Owner	Apr 21	Buy	2.59	38,800	100,492	4,865,924	Apr 25 06:10 AM
MATHER CHARLES E IV	Director	Mar 31	Buy	3.12	4,000	12,460	41,322	Mar 31 09:24 PM
Grant Stuart M.	10% Owner	Feb 22	Buy	2.75	42,000	115,500	4,827,124	Feb 23 10:15 AM
Grant Stuart M.	10% Owner	Feb 18	Buy	2.85	10,000	28,500	4,785,124	Feb 23 10:15 AM
Grant Stuart M.	10% Owner	Feb 07	Buy	2.97	36,030	107,009	4,775,124	Feb 08 01:04 PM
Grant Stuart M.	10% Owner	Dec 15	Buy	3.45	100,000	345,000	4,723,989	Dec 17 09:30 AM
Grant Stuart M.	10% Owner	Nov 16	Buy	3.52	25,000	88,000	4,623,989	Nov 17 07:00 AM
Grant Stuart M.	10% Owner	Nov 15	Buy	3.64	75,000	272,750	4,598,989	Nov 17 07:00 AM
Ianchulev Tsontcho	CHIEF EXECUTIVE OFFICER	Nov 03	Buy	4.04	30,000	121,206	579,895	Nov 03 07:54 PM
MATHER CHARLES E IV	Director	Nov 01	Buy	3.83	4,000	15,314	30,359	Nov 01 05:05 PM
Grant Stuart M.	10% Owner	Oct 29	Buy	3.75	15,505	58,140	4,539,094	Nov 02 06:57 AM
Rowe Michael M	CHIEF OPERATING OFFICER	Oct 27	Buy	4.14	1,200	4,968	5,500	Oct 27 04:02 PM
Grant Stuart M.	10% Owner	Oct 26	Buy	4.00	100,000	400,000	4,523,589	Oct 27 07:42 AM
Grant Stuart M.	10% Owner	Oct 25	Buy	4.00	33,806	135,224	4,423,589	Oct 27 07:42 AM
Rowe Michael M	Chief Operating Officer	Sep 13	Buy	4.40	1,500	6,600	4,300	Sep 13 05:04 PM
Grant Stuart M.	10% Owner	Aug 19	Buy	3.98	50,000	198,984	4,389,783	Aug 23 06:00 AM
Grant Stuart M.	10% Owner	Aug 18	Buy	3.93	924	3,635	4,339,783	Aug 19 06:00 AM
Grant Stuart M.	10% Owner	Aug 17	Buy	4.00	23,419	93,676	4,338,859	Aug 19 06:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience